Last updated on November 2019

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy


Brief description of study

This phase III study is designed to evaluate the role of IL-1 inhibition in combination with docetaxel in subjects with advanced NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy. The randomized III part will be preceded by a safety run-in part in which the recommended dose of the combination of canakinumab and docetaxel will be confirmed.

Clinical Study Identifier: NCT03626545

Find a site near you

Start Over

Novartis Investigative Site

San Giovanni Rotondo, Italy
  Connect »